Evidence map›Paper›PMID 42701103›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026

Netupitant versus aprepitant: model-predicted neurokinin-1 receptor occupancy and implications for long-delayed nausea and vomiting prevention.

Hirotoshi Iihara, Giampaolo Bianchini, Matti Aapro, Luca Licata, Alberto Bernareggi, Rudolph M Navari, Yeon Hee Park, Karin Jordan, María Vidal, Florian Scotté and 3 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hirotoshi IiharaDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan. iihara.hirotoshi.p7@f.gifu-u.ac.jp.ORCID http://orcid.org/0000-0002-4171-454X
Giampaolo BianchiniDepartment of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Matti AaproGenolier Cancer Center, Clinique de Genolier, Genolier, Switzerland.
Luca LicataDepartment of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
Alberto BernareggiClinical Pharmacology Consultant, Concorezzo, Italy.
Rudolph M NavariWorld Health Organization, Mount Olive, AL, USA.
Yeon Hee ParkDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Karin JordanDepartment of Hematology, Oncology and Palliative Medicine, Ernst Von Bergmann Hospital, Potsdam, Germany.
María VidalDepartment of Medical Oncology, Hospital Clinic; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS; Department of Medicine, University of Barcelona, Barcelona, Spain.
Florian ScottéInterdisciplinary Cancer Course Department, Gustave Roussy Cancer Institute, Villejuif, France.
Eric J RoelandOregon Health and Science University, Knight Cancer Institute, Portland, OR, USA.
Lee SchwartzbergRenown Health-Pennington Cancer Institute, University of Nevada, Reno, NV, USA.
Hope S RugoDepartment of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNausea and vomiting beyond 5 days after emetogenic chemotherapy or antibody-drug conjugate (ADC) therapy are common, yet the role of neurokinin-1 (NK

methodsData from previous PK studies were analyzed by compartmental modeling. Positron emission tomography studies assessing striatal NK

resultsModel predicted NK

conclusionsSingle-dose netupitant maintained NK

Indexed as

AntiemeticsMorpholinesNauseaNeurokinin-1 Receptor AntagonistsPyridinesVomitingAdministration, OralAntineoplastic AgentsAprepitantBenzeneacetamidesFemaleHumansMaleModels, BiologicalPiperazinesPositron-Emission TomographyAntiemeticsAntineoplastic AgentsAprepitantBenzeneacetamidesMorpholinesnetupitantNeurokinin-1 Receptor AntagonistsPiperazinesPyridinesReceptors, Neurokinin-1Antibody–drug conjugateAprepitantCINVNauseaNetupitantVomiting

Identifiers

PMID42701103
PMCPMC13546154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.